Expression of p53 and its homolog, p73, in HPV DNA positive oesophageal squamous cell carcinomas

Virology

Volumn 369, Issue 1, 2007, Pages 182-190

  Matsha, T ^a   Donninger, H ^a   Erasmus, R T ^b   Hendricks, D ^a   Stepien, A ^c   Parker, M I ^a  

^a Faculty of Health Sciences   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c WALTER SISULU UNIVERSITY   (South Africa)

Author keywords

Human papilloma virus; Oesophageal cancer; p53; p73

Indexed keywords

PROTEIN P53; PROTEIN P73;

ALCOHOL CONSUMPTION; ARTICLE; DISEASE ASSOCIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUTRITIONAL DEFICIENCY; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SMOKING; VIRUS DETECTION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; HUMANS; NUCLEAR PROTEINS; PAPILLOMAVIRIDAE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

HUMAN PAPILLOMAVIRUS;

EID: 35649008943     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.07.025     Document Type: Article

References (58)

1. Accardi R., Dong W., Smet A., Cui R., Hautefeuille A., Gabet A.S., Sylla B.S., Gissmann L., Hainaut P., and Tommasino M. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep. 7 (2006) 334-340
2. Band V., Dalal S., Delmolino L., and Androphy E.J. Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J. 12 (1993) 1847-1852
3. Brooks L.A., Sullivan A., O'Nions J., Bell A., Dunne B., Tidy J.A., Evans D.J., Osin P., Vousden K.H., Gusterson B., Farrell P.J., Storey A., Gasco M., Sakai T., and Crook T. E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br. J. Cancer 86 (2002) 263-268
4. Brown L.M., Hoover R., Silverman D., Baris D., Hayes R., Swanson G.M., Schoenberg J., Greenberg R., Liff J., Schwartz A., Dosemeci M., Pottern L., and Fraumeni Jr. J.F. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am. J. Epidemiol. 153 (2001) 114-122
5. Cai Y.C., Yang G.Y., Nie Y., Wang L.D., Zhao X., Song Y.L., Seril D.N., Liao J., Xing E.P., and Yang C.S. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis 21 (2000) 683-689
6. Cao W., Chen X., Dai H., Wang H., Shen B., Chu D., McAfee T., and Zhang Z.F. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. Cancer 101 (2004) 834-844
7. Chang F., Syrjanen S., Shen Q., Ji H.X., and Syrjanen K. Human papillomavirus (HPV) DNA in esophageal precancer lesions and squamous cell carcinomas from China. Int. J. Cancer 45 (1990) 21-25
8. Chang F., Syrjanen S., Tervahauta A., Kurvinen K., Wang L., and Syrjanen K. Frequent mutations of p53 gene in oesophageal squamous cell carcinomas with and without human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in oesophageal carcinogenesis. Br. J. Cancer 70 (1994) 346-351
9. Chang F., Syrjanen S., Wang L., Shen Q., and Syrjanen K. p53 overexpression and human papillomavirus (HPV) infection in oesophageal squamous cell carcinomas derived from a high-incidence area in China. Anticancer Res. 17 (1997) 709-715
10. Chen C.L., Ip S.M., Cheng D., Wong L.C., and Ngan H.Y. P73 gene expression in ovarian cancer tissues and cell lines. Clin.Cancer Res. 6 (2000) 3910-3915
11. Chi S.G., Chang S.G., Lee S.J., Lee C.H., Kim J.I., and Park J.H. Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res. 59 (1999) 2791-2793
12. de Villiers E.M., Gunst K., Stein H., and Scherubl H. Esophageal squamous cell cancer in patients with head and neck cancer: prevalence of human papillomavirus DNA sequences. Int. J. Cancer 109 (2004) 253-258
13. Dominguez D., Garcia J.M., Pena C., Silva J., Garcia V., Martinez L., Maximiano C., Gomez M.E., Rivera J.A., Garcia-Andrade C., and Bonilla F. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J. Clin. Oncol. 24 (2006) 805-815
14. Dreilich M., Bergqvist M., Moberg M., Brattstrom D., Gustavsson I., Bergstrom S., Wanders A., Hesselius P., Wagenius G., and Gyllensten U. High-risk human papilloma virus (HPV) and survival in patients with esophageal carcinoma: a pilot study. BMC Cancer 6 (2006) 94
15. Dyson N., Howley P.M., Munger K., and Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 (1989) 934-937
16. Ellis A., Field J.K., Field E.A., Friedmann P.S., Fryer A., Howard P., Leigh I.M., Risk J., Shaw J.M., and Whittaker J. Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family-A review of six generations. Eur. J. Cancer, Part B Oral Oncol. 30B (1994) 102-112
17. Enzinger P.C., and Mayer R.J. Esophageal cancer. N. Engl. J. Med. 349 (2003) 2241-2252
18. Fakhry C., and Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J. Clin. Oncol. 24 (2006) 2606-2611
19. Ferlay, J., Bray, F., Pisani, P., Parkin, D.M., GLOBOCAN, 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No.5. (2.0). 2004. Lyon, IARCPress. Ref Type: Data File.
20. Furihata M., Ohtsuki Y., Ogoshi S., Takahashi A., Tamiya T., and Ogata T. Prognostic significance of human papillomavirus genomes (type-16, -18) and aberrant expression of p53 protein in human esophageal cancer. Int. J. Cancer 54 (1993) 226-230
21. Gamieldien W., Victor T.C., Mugwanya D., Stepien A., Gelderblom W.C., Marasas W.F., Geiger D.H., and van Helden P.D. p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. Int. J. Cancer 78 (1998) 544-549
22. Gao G.F., Roth M.J., Wei W.Q., Abnet C.C., Chen F., Lu N., Zhao F.H., Li X.Q., Wang G.Q., Taylor P.R., Pan Q.J., Chen W., Dawsey S.M., and Qiao Y.L. No association between HPV infection and the neoplastic progression of esophageal squamous cell carcinoma: result from a cross-sectional study in a high-risk region of China. Int. J. Cancer 119 (2006) 1354-1359
23. Gardiol D., Kuhne C., Glaunsinger B., Lee S.S., Javier R., and Banks L. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18 (1999) 5487-5496
24. Harwood C.A., Surentheran T., McGregor J.M., Spink P.J., Leigh I.M., Breuer J., and Proby C.M. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J. Med. Virol. 61 (2000) 289-297
25. Havre P.A., Yuan J., Hedrick L., Cho K.R., and Glazer P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55 (1995) 4420-4424
26. He D., Zhang D.K., Lam K.Y., Ma L., Ngan H.Y., Liu S.S., and Tsao S.W. Prevalence of HPV infection in esophageal squamous cell carcinoma in Chinese patients and its relationship to the p53 gene mutation. Int. J. Cancer 72 (1997) 959-964
27. Hendricks D., and Parker M.I. Oesophageal cancer in Africa. IUBMB.Life 53 (2002) 263-268
28. Kang M.J., Park B.J., Byun D.S., Park J.I., Kim H.J., Park J.H., and Chi S.G. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. Clin. Cancer Res. 6 (2000) 1767-1771
29. Kawaguchi H., Ohno S., Araki K., Miyazaki M., Saeki H., Watanabe M., Tanaka S., and Sugimachi K. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res. 60 (2000) 2753-2755
30. Kiviat N.B. Papillomaviruses in non-melanoma skin cancer: epidemiological aspects. Semin. Cancer Biol. 9 (1999) 397-403
31. Lee J.M., Shun C.T., Wu M.T., Chen Y.Y., Yang S.Y., Hung H.I., Chen J.S., Hsu H.H., Huang P.M., Kuo S.W., and Lee Y.C. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer. Mutat. Res. 594 (2006) 181-188
32. Li X., and Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70 (1996) 4509-4516
33. Li T., Lu Z.M., Guo M., Wu Q.J., Chen K.N., Xing H.P., Mei Q., and Ke Y. p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95 (2002) 2571-2576
34. Liu X., Clements A., Zhao K., and Marmorstein R. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 281 (2006) 578-586
35. Matsha T., Erasmus R., Kafuko A.B., Mugwanya D., Stepien A., and Parker M.I. Human papillomavirus associated with oesophageal cancer. J. Clin. Pathol. 55 (2002) 587-590
36. Moll U.M., and Slade N. p63 and p73: roles in development and tumor formation. Mol. Cancer Res. 2 (2004) 371-386
37. Ng S.W., Yiu G.K., Liu Y., Huang L.W., Palnati M., Jun S.H., Berkowitz R.S., and Mok S.C. Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 19 (2000) 1885-1890
38. Oh S.T., Longworth M.S., and Laimins L.A. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J. Virol. 78 (2004) 2620-2626
39. Parish J.L., Kowalczyk A., Chen H.T., Roeder G.E., Sessions R., Buckle M., and Gaston K. E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death. J. Virol. 80 (2006) 4580-4590
40. Park J.S., Kim E.J., Lee J.Y., Sin H.S., Namkoong S.E., and Um S.J. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int. J. Cancer 91 (2001) 822-827
41. Peixoto Guimaraes D., Hsin L.S., Snijders P., Wilmotte R., Herrero R., Lenoir G., Montesano R., Meijer C.J., Walboomers J., and Hainaut P. Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. Cancer Lett. 162 (2001) 231-235
42. Qi Z.L., Huo X., Xu X.J., Zhang B., Du M.G., Yang H.W., Zheng L.K., Li J., and Shen Z.Y. Relationship between HPV16/18 E6 and 53, 21WAF1, MDM2, Ki67 and cyclin D1 expression in esophageal squamous cell carcinoma: comparative study by using tissue microarray technology. Exp. Oncol. 28 (2006) 235-240
43. Risk J.M., Mills H.S., Garde J., Dunn J.R., Evans K.E., Hollstein M., and Field J.K. The tylosis esophageal cancer (TOC) locus: more than just a familial cancer gene. Dis, Esophagus 12 (1999) 173-176
44. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
45. Shibagaki I., Tanaka H., Shimada Y., Wagata T., Ikenaga M., Imamura M., and Ishizaki K. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin. Cancer Res. 1 (1995) 769-773
46. Si H.X., Tsao S.W., Poon C.S., Wong Y.C., and Cheung A.L. Physical status of HPV-16 in esophageal squamous cell carcinoma. J. Clin. Virol. 32 (2005) 19-23
47. Sun X.F. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin. Cancer Res. 8 (2002) 165-170
48. Syrjanen K.J. HPV infections and oesophageal cancer. J. Clin. Pathol. 55 (2002) 721-728
49. Tannapfel A., Wasner M., Krause K., Geissler F., Katalinic A., Hauss J., Mossner J., Engeland K., and Wittekind C. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J. Natl. Cancer Inst. 91 (1999) 1154-1158
50. Toh Y., Kuwano H., Tanaka S., Baba K., Matsuda H., Sugimachi K., and Mori R. Detection of human papillomavirus DNA in esophageal carcinoma in Japan by polymerase chain reaction. Cancer 70 (1992) 2234-2238
51. Tokuchi Y., Hashimoto T., Kobayashi Y., Hayashi M., Nishida K., Hayashi S., Imai K., Nakachi K., Ishikawa Y., Nakagawa K., Kawakami Y., and Tsuchiya E. The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br. J. Cancer 80 (1999) 1623-1629
52. Ueno T., Sasaki K., Yoshida S., Kajitani N., Satsuka A., Nakamura H., and Sakai H. Molecular mechanisms of hyperplasia induction by human papillomavirus E7. Oncogene 25 (2006) 4155-4164
53. Vikhanskaya F., Toh W.H., Dulloo I., Wu Q., Boominathan L., Ng H.H., Vousden K.H., and Sabapathy K. p73 supports cellular growth through c-Jun-dependent AP-1 transactivation. Nat. Cell Biol. 9 (2007) 698-705
54. Vos M., Adams C.H., Victor T.C., and van Helden P.D. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet. Cytogenet. 140 (2003) 23-30
55. Williamson A.L., Jaskiesicz K., and Gunning A. The detection of human papillomavirus in oesophageal lesions. Anticancer Res. 11 (1991) 263-265
56. Woodman C.B., Collins S.I., and Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat. Rev., Cancer 7 (2007) 11-22
57. Yokomizo A., Mai M., Tindall D.J., Cheng L., Bostwick D.G., Naito S., Smith D.I., and Liu W. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 18 (1999) 1629-1633
58. Zaika A.I., Kovalev S., Marchenko N.D., and Moll U.M. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59 (1999) 3257-3263